Alaunos Therapeutics (TCRT) Accounts Payables (2009 - 2026)
Alaunos Therapeutics' (TCRT) quarterly Accounts Payables came in at $400000.0 in Q1 2026, up 52.67% YoY from $262000.0 in Q1 2025, and down 34.75% on a QoQ basis from $613000.0 in Q4 2025.
Alaunos Therapeutics (TCRT) Accounts Payables (2009 - 2026) Analysis & Trends
Alaunos Therapeutics (TCRT) has 18 years of Accounts Payables data on file, last reported at $400000.0 in Q1 2026.
- Quarterly Accounts Payables rose 52.67% year-over-year to $400000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $400000.0 (up 52.67% YoY) and the FY2025 annual result came in at $613000.0, up 18.8% from the prior year.
- Accounts Payables fell to $400000.0 in Q1 2026, from $613000.0 in the prior quarter.
- In the past five years, Accounts Payables ranged from a high of $2.0 million in Q3 2022 to a low of $262000.0 in Q1 2025.
- A 5-year average of $797882.4 and a median of $605000.0 in 2022 frame the typical range for Accounts Payables.
- Annual changes were most pronounced in 2022 — Accounts Payables slumped 85.56% — and 2023, when it soared 212.03%.
- Tracing TCRT's Accounts Payables over 5 years: stood at $1.4 million in 2022, then slumped by 55.65% to $616000.0 in 2023, then declined by 16.23% to $516000.0 in 2024, then climbed by 18.8% to $613000.0 in 2025, then plunged by 34.75% to $400000.0 in 2026.
- The last three Accounts Payables figures came in at $400000.0 (Q1 2026), $613000.0 (Q4 2025), and $843000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Alaunos Therapeutics | 4.28 Mn | 4.16 Mn | - | 732,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 400,000.00 |
| Dec 31, 2025 | 613,000.00 |
| Sep 30, 2025 | 843,000.00 |
| Jun 30, 2025 | 285,000.00 |
| Mar 31, 2025 | 262,000.00 |
| Dec 31, 2024 | 516,000.00 |
| Sep 30, 2024 | 458,000.00 |
| Jun 30, 2024 | 365,000.00 |
| Mar 31, 2024 | 597,000.00 |
| Dec 31, 2023 | 616,000.00 |
| Sep 30, 2023 | 1.30 Mn |
| Jun 30, 2023 | 1.48 Mn |
| Mar 31, 2023 | 1.38 Mn |
| Dec 31, 2022 | 1.39 Mn |
| Sep 30, 2022 | 1.98 Mn |
| Jun 30, 2022 | 474,000.00 |
| Mar 31, 2022 | 605,000.00 |
| Dec 31, 2021 | 1.37 Mn |
| Sep 30, 2021 | 1.46 Mn |
| Jun 30, 2021 | 982,000.00 |